I dont think we stop with AML or colorectal cancer with NKG2D" CART therapy developer CelyadSA CEO filpetti tells GEN httpow.lyXf6750uD9UIÂ
“I don’t think we stop with AML or colorectal cancer with NKG2D," CAR-T therapy developer @CelyadSA CEO @filpetti tells GEN: http://ow.ly/Xf6750uD9UI
More From BioPortfolio on "“I don’t think we stop with AML or colorectal cancer with NKG2D," CAR-T therapy developer @CelyadSA CEO @filpetti tells GEN: http://ow.ly/Xf6750uD9UI "